Shu Chaoqin, Qin Chen, Wu Aijun, Wang Yufeng, Zhao Chaoqian, Shi Zhe, Niu Huicong, Chen Jiajie, Huang Jimin, Zhang Xinxin, Huan Zhiguang, Chen Lei, Zhu Min, Zhu Yufang
School of Materials and Chemistry, University of Shanghai for Science and Technology, Shanghai, 200093, P. R. China.
State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, 200050, P. R. China.
Adv Healthc Mater. 2024 May;13(13):e2303217. doi: 10.1002/adhm.202303217. Epub 2024 Feb 20.
Osteochondral defects are often accompanied by excessive reactive oxygen species (ROS) caused by osteoarthritis or acute surgical inflammation. An inflammatory environment containing excess ROS will not only hinder tissue regeneration but also impact the quality of newly formed tissues. Therefore, there is an urgent need to develop scaffolds with both ROS scavenging and osteochondral repair functions to promote and protect osteochondral tissue regeneration. In this work, by using 3D printing technology, a composite scaffold based on cobalt-incorporated chloroapatite (Co-ClAP) bioceramics, which possesses ROS-scavenging activity and can support cell proliferation, adhesion, and differentiation, is developed. Benefiting from the catalytic activity of Co-ClAP bioceramics, the composite scaffold can protect cells from oxidative damage under ROS-excessive conditions, support their directional differentiation, and simultaneously mediate an anti-inflammatory microenvironment. In addition, it is also confirmed by using rabbit osteochondral defect model that the Co-ClAP/poly(lactic-co-glycolic acid) scaffold can effectively promote the integrated regeneration of cartilage and subchondral bone, exhibiting an ideal repair effect in vivo. This study provides a promising strategy for the treatment of defects with excess ROS and inflammatory microenvironments.
Theranostics. 2018-2-15
Biomed Mater. 2021-7-29
ACS Appl Mater Interfaces. 2024-7-24
Mater Today Bio. 2025-5-8
Front Bioeng Biotechnol. 2025-3-31
BMC Biotechnol. 2024-4-30